VEGF 165 (AA 27-191) (Active) Protein

Produktnummer ABIN2018445

Produktdetails

Target: VEGF 165

Protein-Typ: Recombinant

Biologische Aktivität: Active

Proteineigenschaft: AA 27-191

Spezies: Human

Quelle: HEK-293T Cells

Produktmerkmale: ED50 <16 ng/mL, measured in a cell proliferation assay using HUVEC cells.

Reinheit: > 95 % as analyzed by SDS-PAGE.

Endotoxin-Niveau: < 0.2 EU/μg, determined by LAL method.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Reconstituted in ddH2O or PBS at 100 μg/mL.

Buffer: Lyophilized after extensive dialysis against PBS.

Lagerung: -80 °C

Informationen zur Lagerung: Lyophilized recombinant Human Vascular Endothelial Growth Factor 165 (VEGF-165) remains stable up to 6 months at -80°C from date of receipt. Upon reconstitution, Human Vascular Endothelial Growth Factor 165 (VEGF-165) should be stable up to 1 week at 4°C or up to 2 months at -20°C.

Haltbarkeit: 6 months

Antigendetails

Target: VEGF 165

Andere Bezeichnung: Vascular Endothelial Growth Factor 165 (VEGF165)

Hintergrund: Vascular Endothelial Growth Factor is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors, fms-like tyrosine kinase (flt-1), KDR gene product (the mouse homolog of KDR is the flk-1 gene product) and the flt4 gene product.
Synonyms: Vascular Endothelial Growth Factor, VPF, Folliculostellate cell-derived growth factor, Glioma-derived endothelial cell mitogen

Molekulargewicht: 20-26 kDa, observed by reducing SDS-PAGE.

NCBI Accession: NP_001165097